Piper Jaffray analyst Sean Wieland downgraded Patheon (PTHN) to Neutral from Overweight and raised his price target to $35 from $33 to reflect the company's agreement to be acquired by Thermo Fisher (TMO). In his downgrade note, Wieland added that Catalent (CTLT) is comparable to Patheon and would trade at $36 if the same valuation as used in Thermo Fisher's deal is applied.
Check out this morning's top movers from around Wall Street, compiled by The Fly. UP AFTER EARNINGS... To see the rest of the story go to thefly.com. See Story Here